Melyd (Glimepiride)

Glimepiride stimulates insulin secretion by binding to the sulfonylurea receptor on pancreatic beta‑cells. This action closes ATP‑sensitive potassium channels, leading to cell depolarization, calcium influx, and the release of insulin, which in turn reduces circulating glucose levels.

The appropriate dose of Melyd is individualized by the prescribing healthcare professional based on factors such as the patient’s age, renal function, glycemic control, and concomitant therapies. The prescriber determines the starting dose and any subsequent adjustments.

Safety of glimepiride in pregnancy and lactation has not been firmly established. It is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their clinician.

To order Melyd, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Glimepiride belongs to the sulfonylurea class, which generally provides a rapid and potent insulin‑secretagogue effect. Compared with newer classes such as DPP‑4 inhibitors, sulfonylureas are often less expensive but carry a higher risk of hypoglycemia and weight gain. Choice of therapy depends on individual patient characteristics and treatment goals.

Melyd should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency throughout its shelf life.

Melyd is taken orally, usually as a tablet swallowed whole with a glass of water. It may be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional to ensure consistent absorption.

The most critical safety concerns are severe hypoglycemia, which can be life‑threatening, and rare allergic reactions such as Stevens‑Johnson syndrome. Hepatic dysfunction and blood‑cell abnormalities have also been reported, so regular monitoring is advisable.

Melyd is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, known hypersensitivity to sulfonylureas, or severe renal or hepatic impairment. Patients with these conditions should discuss alternative therapies with their physician.